Fisher Asset Management LLC Cuts Position in DexCom, Inc. (NASDAQ:DXCM)

Fisher Asset Management LLC lowered its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 991,519 shares of the medical device company's stock after selling 20,103 shares during the quarter. Fisher Asset Management LLC owned about 0.26% of DexCom worth $123,038,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Valley National Advisers Inc. grew its stake in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company's stock worth $30,000 after buying an additional 103 shares during the last quarter. MV Capital Management Inc. increased its position in DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company's stock valued at $34,000 after acquiring an additional 138 shares during the period. Washington Trust Advisors Inc. lifted its holdings in shares of DexCom by 120.6% during the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company's stock worth $44,000 after purchasing an additional 193 shares during the period. Turtle Creek Wealth Advisors LLC bought a new stake in shares of DexCom in the fourth quarter worth $57,000. Finally, NBC Securities Inc. acquired a new stake in DexCom in the third quarter valued at $47,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

DXCM traded up $1.72 during midday trading on Friday, hitting $128.37. The stock had a trading volume of 1,778,971 shares, compared to its average volume of 3,031,548. The company has a market cap of $51.05 billion, a P/E ratio of 82.82, a price-to-earnings-growth ratio of 2.15 and a beta of 1.23. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The business has a fifty day moving average of $132.11 and a 200 day moving average of $119.96.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, equities analysts forecast that DexCom, Inc. will post 1.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on DXCM shares. UBS Group upped their price target on DexCom from $153.00 to $163.00 and gave the company a "buy" rating in a research report on Wednesday, April 10th. StockNews.com upgraded shares of DexCom from a "hold" rating to a "buy" rating in a report on Wednesday. Raymond James increased their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a "strong-buy" rating in a research report on Friday, April 26th. Citigroup boosted their target price on DexCom from $148.00 to $161.00 and gave the company a "buy" rating in a research report on Wednesday, April 3rd. Finally, Canaccord Genuity Group increased their price target on DexCom from $144.00 to $145.00 and gave the stock a "buy" rating in a report on Friday, April 26th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $141.67.

Insider Activity

In other DexCom news, CFO Jereme M. Sylvain sold 3,363 shares of the business's stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares of the company's stock, valued at $8,304,405.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the transaction, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Jon Brown sold 629 shares of the stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the sale, the executive vice president now owns 68,212 shares of the company's stock, valued at approximately $8,611,765. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 190,004 shares of company stock worth $25,610,270. Corporate insiders own 0.41% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.